---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004869"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:37:41.147204+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioCryst CEO Jon Stonehouse to retire Dec 31; Charlie Gayer named successor

## Summary
- Jon Stonehouse retiring as CEO on Dec 31, 2025; will remain on BioCryst board.
- Charlie Gayer appointed President (Aug 1, 2025) and CEO (Jan 1, 2026); previously CCO.
- Gayer's base salary rises to $675k as President; expected $775k as CEO with 85% AIP target.
- Gayer elected to board effective Jan 1, 2026; board size increased from nine to ten.
- Stonehouse cited no disagreement; transition follows succession planning process.

## SEC filing metadata
- accession: 0001171843-25-004869
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184325004869/0001171843-25-004869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184325004869/f8k_073125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004869
- JSON: https://secwatch.observer/filing/0001171843-25-004869.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.